| Outcome Measures: |
Primary: Primary efficacy index : The change of hemoglobin concentration of experimental group from baseline to the end of 4th and 6th week, Day 1~4th week & Day 1~6th week|Primary efficacy index: The difference of hemoglobin concentration between the experimental group and the placebo group at the end of 4th and 6th week;, Day 1~4th week & Day 1~6th week|Primary efficacy index: hemoglobin concentration change from baseline to the end of first stage, The amount of change in hemoglobin concentration from baseline to the end of the first stage, Day 1~18th week|Primary efficacy index: hemoglobin concentration change from baseline to the evaluation periods in the second stage (39th ~46th week), The amount of change in hemoglobin concentration from baseline to the evaluation periods in the second stage (39th \~46th week)., Day 1~ evaluation periods (39th ~46th week) | Secondary: Secondary efficacy index: the optimal dosage, The optimal dosage of the subjects at the end of the first stage and the evaluation period (39th \~46th week) in the second stage, the end of 18th week & 39th ~46th week|Secondary efficacy index: maintenance rate, the proportion of subjects whose average Hb concentration remain within the target range during the evaluation period, 39th-46th week|Secondary efficacy index : Proportion of subjects with unstable Hb during the evaluation period, 39th-46th week|Secondary efficacy index: proportion of times of Hb remains within the target range, the proportion of times the measured Hb concentration remains within the target range during the evaluation period;, 39th-46th week|Secondary efficacy index: EPO dose conversion coefficient of RD01, EPO dose conversion factor for subjects at the end of the first stage and evaluation periods in the second stage, end of 18th week & 39th ~46th week|Safety indicator: adverse events, the type, proportion and severity of adverse events, for 46 weeks|Immunogenicity indicator: incidence of anti-RD01 antibodies, incidence of anti-RD01 antibodies, for 46 weeks|Maximum Plasma Concentration (Cmax), the Cmax of RD01 in patients with long-term medication., for 46 weeks|Area Under the Curve (AUC), the AUC of RD01 in patients with long-term medication., for 46 weeks
|
